معرفی
Gregory Thatcher is a Professor in the Department of Pharmacology and Toxicology at the University of Arizona's College of Pharmacy, affiliated with the Skaggs Pharmaceutical Sciences Center. He holds a PhD from the University of Toronto (1986) and a BSc from the University of Manchester (1981), with postdoctoral experience at the University of Sheffield and Oxford University. His research focuses on small molecule therapeutics, drug discovery, and translational medicine.
Dr. Thatcher founded a campus-wide drug discovery center at the University of Illinois at Chicago (UIC) in 2013, advancing academic drug discovery in the Chicagoland region. He launched a biotech startup in 1997, advancing an Alzheimer’s drug to clinical trials. His NIH-funded research (since 2003 via NCI, NIA, NHLBI, NIAID) has produced over 170 publications and numerous patents. Two compounds, Rintodestrant and TTC-352, reached Phase 1 clinical trials for metastatic breast cancer in 2019.
He maintains a lab actively involved in developing novel therapeutic strategies, with a focus on oncology and neurodegenerative diseases. His work bridges academia and industry, emphasizing translational research and clinical impact.
